Jia Jie Biomedical Co., Ltd. AI Stock Analysis
Jia Jie Biomedical Co., Ltd. (4109) AI Stock Analysis
Jia Jie Biomedical Co., Ltd.
(TPEx:4109)
Jia Jie Biomedical scores in the lower band. The primary drag is weak core profitability and cash generation: revenue declined ~10%, margins compressed, operating profit was near zero, and free cash flow turned sharply negative as heavy capital spending outpaced modest operating cash flow — leaving reported profits reliant on non-operating items. Technicals reinforce caution, with the price below all key moving averages and negative MACD momentum, though deeply oversold readings suggest the selling may be extended. Valuation is unattractive at 255x earnings, only partly cushioned by a ~2% dividend yield. The key offset is an exceptionally strong, nearly debt-free balance sheet that gives the company the capacity to fund its investment phase and absorb earnings volatility. Investors should watch for revenue stabilisation, margin recovery and improved conversion of profits into cash.
Jia Jie Biomedical Co., Ltd. (4109) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.21B
- Dividend Yield
- 1.95%
- Average Volume (3M)
- 135.49K
- Price to Earnings (P/E)
- 256.3
- Beta (1Y)
- 0.38
- Revenue Growth
- 13.00%
- EPS Growth
- 902.22%
- Country
- TW
- Employees
- 67
- Sector
- General
- Sector Strength
- 55
- Industry
- Packaged Foods
Jia Jie Biomedical Co., Ltd. Business Overview & Revenue Model
Company Description
Jia Jie Biomedical Co., Ltd., headquartered in Kaohsiung, Taiwan, was established in 1995. Formerly known as Murad Chia Jei Biotechnology Co., Ltd. until its rebranding in June 2019, the company primarily specializes in the production and distributio...
Jia Jie Biomedical Co., Ltd. Financial Statement Overview
Summary
A fortress balance sheet (score 78) is the standout: debt-to-equity of just 3%, equity funding ~89% of assets, and steadily rising equity to NT$1.68 billion. However, earnings quality is weak (income statement score 44) — revenue fell ~10% to NT$485 million, gross margin compressed from ~37% to ~31%, and operating profit was essentially break-even at NT$0.7 million, meaning most of the NT$50 million net income came from non-operating items. Cash flow is the weakest link (score 32), with operating cash flow halving to NT$21 million, poor profit-to-cash conversion (~NT$0.12 per NT$1 of net income), and free cash flow swinging to negative NT$64 million on NT$86 million of capital spending. Return on equity also slipped to ~3%, signalling inefficient use of a large capital base.
Income Statement
44NeutralBalance Sheet
78PositiveCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 514.65M | 485.40M | 537.07M | 332.76M | 317.72M | 242.48M |
| Gross Profit | 137.84M | 150.34M | 173.35M | 117.64M | 116.51M | 83.77M |
| EBITDA | 60.57M | 18.24M | 241.93M | 161.30M | 12.12M | 18.58M |
| Net Income | 4.17M | 50.26M | 211.37M | 144.15M | -5.47M | 5.34M |
Balance Sheet | ||||||
| Total Assets | 1.88B | 1.89B | 1.48B | 1.41B | 1.00B | 1.02B |
| Cash, Cash Equivalents and Short-Term Investments | 500.33M | 481.56M | 263.05M | 384.17M | 253.75M | 286.31M |
| Total Debt | 87.85M | 52.96M | 8.78M | 76.75M | 3.73M | 5.27M |
| Total Liabilities | 223.60M | 174.89M | 123.08M | 342.69M | 80.00M | 86.47M |
| Stockholders Equity | 1.62B | 1.68B | 1.33B | 1.05B | 897.98M | 907.87M |
Cash Flow | ||||||
| Free Cash Flow | -52.35M | -64.15M | 24.72M | -13.10M | -26.64M | 2.85M |
| Operating Cash Flow | 13.04M | 21.34M | 44.35M | -4.49M | -8.78M | 4.37M |
| Investing Cash Flow | -121.67M | -186.12M | -128.15M | 2.55M | -35.02M | -173.05M |
| Financing Cash Flow | 28.78M | 348.51M | -158.77M | 234.57M | -3.73M | -2.48M |
Jia Jie Biomedical Co., Ltd. Peers Comparison
Overall Rating
TW:684655Neutral
TW:413348Neutral- TW:410945Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6846 | 55Neutral | TWD 1.33B | 12.56 | ― | 8.05% | -3.09% | -27.22% |
| TW:4133 | 48Neutral | TWD 1.20B | 27.03 | ― | 0.56% | -4.19% | ― |
| TW:4109 | 45Neutral | TWD 1.21B | 256.25 | ― | 1.95% | 13.00% | 902.22% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4109 | Jia Jie Biomedical Co., Ltd. | 10.25 | -5.46 | -34.76% | |
| TW:4133 | Abnova Taiwan Corp. | 20.00 | -3.27 | -14.07% | |
| TW:6564 | Enimmune corporation | 14.90 | -5.67 | -27.55% | |
| TW:6677 | Anxo Pharmaceutical Co., Ltd. | 20.95 | -3.15 | -13.07% | |
| TW:6846 | Greenyn Biotechnology Co., Ltd. | 49.00 | -24.13 | -32.99% | |
| TW:7814 | Horien Biochemical Technology Co., Ltd. | 27.30 | -13.00 | -32.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026